Small-Molecule inhibitors of the type III secretion system

Molecules

Volumn 20, Issue 9, 2015, Pages 17659-17674

  Gu, Lingling ^a   Zhou, Shanshan ^a   Zhu, Lanping ^a   Liang, Cuirong ^a   Chen, Xin ^a  

^a CHANGZHOU UNIVERSITY   (China)

Author keywords

Antibacterial agents; Effector proteins; Gram negative bacteria; Pathogens; Small molecule inhibitors; Type III secretion system; Virulence

Indexed keywords

ANTIINFECTIVE AGENT; MOLECULAR LIBRARY; TYPE III SECRETION SYSTEM;

ANTAGONISTS AND INHIBITORS; ANTIBIOTIC RESISTANCE; CHEMISTRY; DRUG EFFECTS; GRAM NEGATIVE BACTERIUM; METABOLISM; MOLECULAR LIBRARY; PHARMACOLOGY; TYPE III SECRETION SYSTEM; VIRULENCE;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; GRAM-NEGATIVE BACTERIA; SMALL MOLECULE LIBRARIES; TYPE III SECRETION SYSTEMS; VIRULENCE;

EID: 84942693852     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules200917659     Document Type: Review

References (62)

1. Cegelski, L.; Marshall, G.R.; Eldridge, G.R.; Hultgren, S.J. The biology and future prospects ofantivirulence therapies. Nat. Rev. Microbiol. 2008, 6, 17-27.
2. Escaich, S. Antivirulene as a new antibacterial approach for chemotherapy. Curr. Opin. Chem. Biol.2008, 12, 400-408.
3. Rasko, D.A.; Sperandio, V. Anti-virulene strategies to combat bacteria-mediated disease. Nat. Rev.Drug Discov. 2010, 9, 117-128.
4. Desvaux, M.; Hebraud, M.; Henderson, I.R.; Pallen, M.J. Type III secretion: What's in a name?Trends Microbiol. 2006, 14, 157-160.
5. Coburn, B.; Sekirov, I.; Finlay, B.B. Type III secretion systems and disease. Clin. Microbiol. Rev.2007, 20, 535-549.
6. Tang, X.Y.; Xiao, Y.M.; Zhou, J.M. Regulation of the type III secretion system in phytopathogenicbacteria. Mol. Plant Microbe Interact. 2006, 19, 1159-1166.
7. Waterman, S.R.; Holden, D.W. Functions and effectors of the Salmonella pathogenicity island 2type III secretion system. Cell. Microbiol. 2003, 5, 501-511.
8. Yip, C.K.; Strynadka, N.C. New structural insights into the bacterial type III secretion system. Trends Biochem. Sci. 2006, 31, 223-230.
9. Schraidt, O.; Marlovits, T.C. Three-dimensional model of Salmonella's needle complex at subnamometer resolution. Science 2011, 331, 1192-1195.
10. Okada, N.; Iida, T.; Park, K.S.; Goto, N.; Yasunaga, T.; Hiyoshi, H.; Matsuda, S.; Kodama, T.;Honda, T. Identification and characterization of a novel type III secretion system in trh-positivevibrio parahaemolyticus strain TH3996 reveal genetic lineage and diversity of pathogenic machinerybeyond the species level. Infect. Immun. 2009, 77, 904-913.
11. Cornelis, G.R. The type III secretion injectisome, a complex nanomachine for intracellular toxin delivery. Biol. Chem. 2010, 391, 745-751.
12. Chatterjee, S.; Chaudhury, S.; McShan, A.C.; Kaur, K.; Guzman, N.D. Structure and biophysicsof type III secretion in bacteria. Biochemistry 2013, 52, 2508-2517.
13. Tamano, K.; Aizawa, S.I.; Katayama, E.; Nonaka, T.; Imajoh-Ohmi, S.; Kuwae, A.; Nagai, S.;Sasakawa, C. Supramolecular structure of the Shigella type III secretion machinery: The needlepart is changeable in length and essential for delivery of effectors. EMBO J. 2000, 19, 3876-3887.
14. Spreter, T.; Yip, C.K.; Sanowar, S.; Andre I.; Kimbrough, T.G.; Vuckovic, M.; Pfuetzner, R.A.;Deng, W.; Yu, A.C.; Finlay, B.B.; et al. A conserved structural motif mediates formation of theperiplasmic rings in the type III secretion system. Nat. Struct. Mol. Biol. 2009, 16, 468-476.
15. Galan, J.E.; Wolf-Watz, H. Protein delivery into eukaryotic cells by type III secretion machines.Nature 2006, 444, 567-573.
16. Loquet, A.; Sgourakis, N.G.; Gupta, R.; Giller, K.; Riedel, D.; Goosmann, C.; Griesinger, C.; Kolbe, M.; Baker, D.; Becker, S.; et al. Atomic model of the type III secretion system needle.Nature 2012, 486, 276-279.
17. Akeda, Y.; Galan, J.E. Chaperone release and unfolding of substrates in type III secretion. Nature 2005, 437, 911-915.
18. Izore, T.; Job, V.; Dessen, A. Biogenesis, regulation, and targeting of the type III secretion system.Structure 2011, 19, 603-612.
19. Feldman, M.F.; Muller, S.; Wuest, E.; Cornelis, G.R. SycE allows secretion of YopE-DHFR hybrids by the Yersinia enterocolitica type III Ysc system. Mol. Micrbiol. 2002, 46, 1183-1197.
20. Schraidt, O.; Lefebre, M.D.; Brunner, M.J.; Schmied, W.H.; Schmidt, A.; Radics, J.; Mechtler, K.;Galan, J.E.; Marlovits, T.C. Topology and organization of the Salmonella typhimurium type IIIsecretion needle complex components. PLoS Pathog. 2010, 6, e1000824.
21. Marlovits, T.C.; Kubori, T.; Sukhan, A.; Thomas, D.R.; Galan, J.E.; Unger, V.M. Structural insightsinto the assembly of the type III secretion needle complex. Science 2004, 306, 1040-1042.
22. Marlovits, T.C.; Kubori, T.; Lara-Tejero, M.; Thomas, D.; Unger, V.M.; Galan, J.E. Assembly ofthe inner rod determines needle length in the type III secretion injectisome. Nature 2006, 441, 637-640.
23. Galan, J.E. Salmonella interactions with host cells: Type III secretion at work. Annu. Rev. CellDev. Biol. 2001, 17, 53-86.
24. Tsou, L.K.; Dossa, P.D.; Hang, H.C. Small molecules aimed at type III secretion systems to inhibitbacterial virulence. Med. Chem. Commun. 2013, 4, 68-79.
25. Milla, C.E.; Chmiel, J.F.; Accurso, F.J.; van Devanter, D.R.; Konstan, M.W.; Yarranton, G.; Geller, D.E. Anti-PcrV antibody in cystic fibrosis: A novel approach targeting Pseudomonas aeruginosa airway infection. Pediatr. Pulmonol. 2014, 49, 650-658.
26. Pettersson, J.; Nordfelth, R.; Dubinina, E.; Bergman, T.; Gustafsson, M.; Magnusson, K.E.; Wolf-Watz, H. Modulation of virulence factor expression by pathogen target cell contact. Science 1996, 273, 1231-1233.
27. Kauppi, A.M.; Nordfelth, R.; Uvell, H.; Wolf-Watz, H.; Elofsson, M. Targeting bacterial virulence: Inhibitors of type III secretion in Yersinia. Chem. Biol. 2003, 10, 241-249.
28. Nordfelth, R.; Kauppi, A.M.; Norberg, H.A.; Wolf-Watz, H.; Elofsson, M. Small-molecule inhibitors specifically targeting type III secretion. Infect. Immun. 2005, 73, 3104-3114.
29. Keyser, P.; Elofsson, M.; Rosell, S.; Wolf-Watz, H. Virulence blockers as alternatives to antibiotics:Type III secretion inhibitors against Gram-negative bacteria. J. Intern. Med. 2008. 264, 17-29.
30. Muschiol, S.; Bailey, L.; Gylfe, A.; Sundin, C.; Hultenby, K.; Bergstro, S.; Elofsson, M.; Wolf-Watz, H.; Normark, S.; Normark, H.B. A small-molecule inhibitor of type III secretion inhibitsdifferent stages of the infectious cycle of Chlamydia trachomatis. Proc. Natl. Acad. Sci. USA 2006, 103, 14566-14571.
31. Gauthier, A.; Robertson, M.L.; Lowden, M.; Ibarra, J.A.; Puente, J.L.; Finlay, B.B. Transcriptional inhibitor of virulence factors in enteropathogenic Escherichia coli. Antimicrob. Agents Chemother. 2005, 49, 4101-4109.
32. Hudson, D.L.; Layton, A.N.; Field, T.R.; Bowen, A.J.; Wolf-Watz, H.; Elofsson, M.; Stevens, M.P.;Galyov, E.E. Inhibition of type III secretion in Salmonella enterica serovar typhimurium bysmall-molecule inhibitors. Antimicrob. Agents Chemother. 2007, 51, 2631-2635.
33. Hoe, N.P.; Minion, F.C.; Goguen, J.D. Temperature sensing in Yersinia pestis: Regulation of yopE transcription by lcrF. J. Bacteriol. 1992, 174, 4275-4286.
34. Kim, O.K.; Garrity-Ryan, L.K.; Bartlett, V.J.; Grier, M.C.; Verma, A.K.; Medjanis, G.; Donatelli, J.E.; Macone, A.B.; Tanaka, S.K.; Levy, S.B.; et al. N-Hydroxybenzimidazole inhibitorsof the transcription factor LcrF in Yersinia: Novel antivirulence agents. J. Med. Chem.2009, 52, 5626-5634.
35. Cornelis, G.R.; Wolf-Watz, H. The Yersinia Yop virulon: A bacterial system for subverting eukaryotic cells. Mol. Microbiol. 1997, 23, 861-867.
36. Logsdon, L.K.; Mecsas, J. Requirement of the Yersinia pseudotuberculosis effectors YopH andYopE in colonization and persistence in intestinal and lymph tissues. Infect. Immun. 2003, 71, 4595-4607.
37. Mota, L.J.; Cornelis, G.R. The bacterial injection kit: Type III secretion systems. Ann. Med. 2005, 37, 234-249.
38. Monack, D.M.; Mecsas, J.; Bouley, D.; Falkow, S. Yersinia-induced apoptosis in vivo aids in theestablishment of a systemic infection of mice. J. Exp. Med. 1998, 188, 2127-2137.
39. Hawley, R.J.; Eitzen, E.M. Biological weapons-a primer for microbiologists. Annu. Rev. Microbiol. 2001, 55, 235-253.
40. Gardiner, J.M.; Procter, J. Synthesis of N-alkoxybenzimidazoles with differentiated C2 and O-substituents. Tetrahedron Lett. 2001, 42, 5109-5111.
41. Ellison, D.W.; Miller, V.L. Regulation of virulence by members of the MarR/SlyA family. Curr. Opin. Microbiol. 2006, 9, 153-159.
42. Hong, M.; Fuangthong, M.; Helmann, J.D.; Brennan, R.G. Structure of an OhrR-ohrA operator complex reveals the DNA binding mechanism of the MarR family. Mol. Cell. 2005, 20, 131-141.
43. Garrity-Ryan, L.K.; Kim, O.K.; Balada-Llasat, J.M.; Bartlett, V.J.; Verma, A.K.; Fisher, M.L.;Castillo, C.; Songsungthong, W.; Tanaka, S.K.; Levy, S.B.; et al. Small molecule inhibitors ofLcrF, a Yersinia pseudotuberculosis transcription factor, attenuate virulence and limit infection ina murine pneumonia model. Infect. Immun. 2010, 78, 4683-4690.
44. Shaver, C.M.; Hauser, A.R. Relative contributions of Pseudomonas aeruginosa ExoU, ExoS, andExoT to virulence in the lung. Infect. Immun. 2004, 72, 6969-6977.
45. Aiello, D.; Williams, J.D.; Majgier-Baranowska, H.; Patel, I.; Peet, N.P.; Huang, J.; Lory, S.; Bowlin, T.L.; Moir, D.T. Discovery and characterization of inhibitors of Pseudomonas aeruginosatype III secretion. Antimicrob. Agents Chemother. 2010, 54, 1988-1999.
46. Zhang, C.F.; Wu, X.G.; Li, Yan; Liang, C.R.; Che, Y.Z.; Gu, L.L.; Ren, J.; Hu, K.; Sun, X.Q.;Yang, C.H.; et al. Synthesis and bioactivity of novel inhibitors for type III secretion system ofPseudomonas aeruginosa PAO1. Chin. J. Org. Chem. 2013, 33, 1309-1318.
47. Felise, H.B.; Nguyen, H.V.; Pfuetzner, R.A.; Barry, K.C.; Jackson, S.R.; Blanc, M.P.; Bronstein, P.A.; Kline, T.; Miller, S.I. An inhibitor of Gram-negative bacterial virulence protein secretion. Cell Host Microbe 2008, 4, 325-336.
48. Kline, T.; Felise, H.B.; Barry, K.C.; Jackson, S.R.; Nguyen, H.V.; Miller, S.I. Substituted 2-imino-5-arylidenethiazolidin-4-one inhibitors of bacterial type III secretion. J. Med. Chem. 2008, 51, 7065-7074.
49. Kline, T.; Barry, K.C.; Jackson, S.R.; Felise, H.B.; Nguyen, H.V.; Miller, S.I. Tethered thiazolidinone dimers as inhibitors of the bacterial type III secretion system. Bioorg. Med. Chem. Lett. 2009, 19, 1340-1343.
50. Aoki, T.; Akashi, T.; Ayabe, S.I. Flavonoids of leguminous plants: Structure, biological activity, and biosynthesis. J. Plant Res. 2000, 113, 475-488.
51. Li, Y.; Peng, Q.; Selimi, D.; Wang, Q.; Charkowski, A.O.; Chen, X.; Yang, C.H. The plant phenolic compound p-coumaric acid represses gene expression in the Dickeya dadantii type III secretion system. Appl. Enviro. Microbiol. 2009, 75, 1223-1228.
52. Li, Y.; Hutchins, W.C.; Wu, X.; Liang, C.; Zhang, C.; Yuan, X.; Khokhani, D.; Chen, X.; Che, Y.; Wang, Q.; et al. Derivatives of plant phenolic compound inhibits the type III secretion system of Dickeya dadantii via HrpX/HrpY two-component signal transduction and Rsm system. Mol. Plant Pathol. 2015, 16, 150-163.
53. Yamazaki, A.; Li, J.; Zeng, Q.; Khokhani, D.; Hutchins, W.C.; Yost, A.C.; Biddle, E.; Toone, E.J.;Chen, X.; Yang, C.H. Derivatives of plant phenolic compound affect the type III secretion systemof Pseudomonas aeruginosa via a GacS/GacA two component signal transduction system.Antimicrob. Agents Chemother. 2012, 56, 36-43.
54. Norelli, J.L.; Jones, A.L.; Aldwinckle, H.S. Fire blight management in the twenty-first century:Using new technologies that enhance host resistance in apple. Plant Dis. 2003, 87, 756-765.
55. Mc Manus, P.S.; Stockwell, V.O.; Sundin, G.W.; Jones, A.L. Antibiotic use in plant agriculture.Annu. Rev. Phytopathol. 2002, 40, 443-463.
56. Khokhani, D.; Zhang, C.F.; Li, Y.; Wang, Q.; Zeng, Q.; Yamazaki, A.; Hutchins, W.; Zhou, S.S.;Chen, X.; Yang, C.H. Discovery of plant phenolic compounds that act as type III secretion systeminhibitors or inducers of the fire blight pathogen, Erwinia amylovora. Appl. Environ. Microbiol.2013, 79, 5424-5436.
57. Grado, M.; Rosenberger, C.M.; Gauthier, A.; Vallance, B.A.; Finlay, B.B. Enteropathogenic Escherichia coli infection induces expression of the early growth response factor by activating mitogen-activated protein kinase cascades in epithelial cells. Infect. Immun. 2001, 69, 6217-6224.
58. Linington, R.G.; Robertson, M.; Gauthier, A.; Finlay, B.B.; van Soest, R.; Andersen, R.J. Caminoside A, an antimicrobial glycolipid isolated from the marine sponge Caminus sphaeroconia.Org. Lett. 2002, 4, 4089-4092.
59. Linington, R.G.; Robertson, M.; Gauthier, A.; Finlay, B.B.; MacMillan, J.B.; Molinski, T.F.; van Soest, R.; Andersen, R.J. Caminosides B-D, antimicrobial glycolipids isolated from the marinesponge Caminus sphaeroconia. J. Nat. Prod. 2006, 69, 173-177.
60. Iwatsuki, M.; Uchida, R.; Yoshijima, H.; Ui, H.; Shiomi, K.; Matsumoto, A.; Takahashi, Y.; Abe, A.;Tomoda, H.; Omura, S. Guadinomines, type III secretion system inhibitors, produced by Streptomycessp. K01-0509 I. Taxonomy, fermentation, isolation and biological properties. J. Antibiot. 2008, 61, 222-229.
61. Iwatsuki, M.; Uchida, R.; Yoshijima, H.; Ui, H.; Shiomi, K.; Kim, Y.P.; Hirose, T.; Sunazuka, T.;Abe, A.; Tomoda, H.; et al. Guadinomines, type III secretion system inhibitors, produced byStreptomyces sp. K01-0509 II. Physico-chemical properties and structure elucidation. J. Antibiot.2008, 61, 230-236.
62. Kimura, K.; Iwatsuki, M.; Nagai, T.; Matsumoto, A.; Takahashi, Y.; Shiomi, K.; Omura, S.; Abe, A. A small-molecule inhibitor of the bacterial type III secretion system protects against in vivoinfection with Citrobacter rodentium. J. Antibiot. 2011, 64, 197-203.